← all environments

Eligibility-Criteria Authoring

Clinical / MedicalMedical monitor

Given an investigational drug (mechanism/class, known/anticipated safety liabilities, indication, and phase), author a clinical-trial inclusion/exclusion criteria list that balances patient safety against enrollability — protecting against the drug's specific risks (CRS/ICANS, ILD/LVEF, infection/VTE, hyperglycemia/hepatotoxicity) without being so restrictive the trial cannot enroll. The agent has read-only reference tools — drug safety profiles, precedent eligibility criteria from analogous trials, and standard organ-function lab thresholds — and must pull and reason itself. This is a judgment/authoring workflow graded by rubric; there is no clean answer key.

Why this is fundable

Scarce expert who grades this
Medical monitor / clinical-development physician (MD, ~$300–500/hr loaded)
What one decision is worth
I/E criteria decide whether a trial enrolls and whether patients are harmed: too loose risks a safety death and a clinical hold; too tight burns 12+ months and millions in re-enrollment.
Real-world data sources
Protocols & SAPs from analogous approved/late-stage trials, drug-class safety labels, standard organ-function thresholds. Curated reference here; maps onto real protocol libraries.

Agent tools

list_drug_classeslist_indicationsget_safety_profileget_precedent_criteriaget_lab_thresholds

Expert grading rubric

Dimension5 (excellent)1 (poor)
Safety-driven exclusionsAuthors exclusions that specifically protect against THIS drug's liabilities, grounded in its pulled safety profile — e.g. for a DLL3 TCE, excludes active CNS mets and poor cardiac/pulmonary reserve for CRS/ICANS; for a HER2 ADC, hard-excludes ILD history; for a JAK inhibitor, excludes untreated TB/active infection and prior VTE.Generic exclusions that ignore the drug's mechanism, or misses the headline class risk (e.g. no ILD exclusion for a deruxtecan-class ADC; no infection screen for a JAK inhibitor).
Organ-function / lab thresholdsSpecifies appropriate, justified organ-function cutoffs (ANC, platelets, hemoglobin, bilirubin, AST/ALT, creatinine clearance, LVEF, QTc, HbA1c) tied to the drug's toxicities and the precedent thresholds — e.g. tighter LFT/glucose cutoffs for a hepatotoxic/hyperglycemic PI3Ki, LVEF for a cardiotoxic ADC.Arbitrary or missing thresholds, copies generic numbers without tying them to the drug's risks, or sets cutoffs that are clinically implausible.
Enrollability balanceKeeps the target population realistically enrollable — relaxes thresholds where precedent allows (marrow involvement, liver mets, Gilbert's; treated/stable brain mets), and does not stack so many exclusions that the trial cannot accrue. Explicitly reasons about the safety-vs-enrollability trade-off.Over-restrictive: excludes the realistic target population into infeasibility (e.g. bars all prior lines, all brain mets, demands pristine organ function) with no enrollability reasoning; or the opposite, ignores safety to maximize accrual.
Precedent alignment & completenessCovers the standard I/E domains for the indication (histologic confirmation, ECOG, measurable disease per RECIST, washout, prior-line definition, life expectancy) and is consistent with the analogous-trial precedent it pulled.Omits whole standard domains (no performance status, no washout, no disease confirmation), or contradicts the precedent criteria for the indication.
Evidence faithfulness & clarityGrounds each criterion in the pulled safety/precedent/threshold data rather than memory; criteria are unambiguous and operational (measurable, with explicit values, timeframes, and units a site could screen against).Fabricates risks or thresholds not in the data, contradicts the tool outputs, or writes vague, non-operational criteria a coordinator could not apply.

Example queries

Trajectories

model panel (compare side by side)

ModelProviderTierJudge 1–5Verdict
Claude Opus 4.8anthropicfrontier4.8strong
GPT (frontier)openaifrontier4.8strong
Claude Haiku 4.5anthropicsmall4.4strong
GPT-4o miniopenaismall4.0acceptable

batch 20260606_021119

QueryModelTool callsTimeStatus
Author the inclusion/exclusion criteria for a Phase 1 first-in-human trial of a DLL3 T-cclaude-opus-4-8338.5sok
Author the inclusion/exclusion criteria for a Phase 3 trial of an anti-HER2 antibody-druclaude-opus-4-8347.4sok
Author the inclusion/exclusion criteria for a Phase 2 trial of a JAK inhibitor in moderaclaude-opus-4-8340.4sok
Author the inclusion/exclusion criteria for a Phase 1/2 trial of a PI3K-alpha inhibitor claude-opus-4-8339.4sok